| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 2290.0 | 2122.5 | 1928.8 |
| Other income | 23.7 | 20.5 | 11.9 |
| Total income | 2313.7 | 2143.0 | 1940.7 |
| Profit before exceptional items & tax | 189.7 | 133.1 | 209.3 |
| Exceptional items | 13.7 | 39.7 | 3.3 |
| Profit before tax | 176.0 | 93.4 | 206.0 |
| Net profit | 119.3 | 55.8 | 151.3 |
| Operating margin | 7.6% | 4.4% | 10.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -21.20% |
|---|---|
| Net profit, quarter on quarter | +113.80% |
| Revenue, year on year | +18.70% |
BSE results filing, NSE: JUBLPHARMA. Figures extracted from the filing.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹975.00
- Market cap
- ₹15,530 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 44.1×Sector 47.4×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Business Update
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Legal & Regulatory
Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.
- Value
- ₹87.31 Cr
Jubilant Pharmova Legal & Regulatory
Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.
- Value
- ₹105.5 Cr
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.
Jubilant Pharmova Production Started
Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.